SOAT1 and myeloproliferative disorder: The landmark discovery of the JAK2V617F mutation ushered a new era in the biology of MPN and established for the first time a link between an acquired genetic hit affecting the neoplastic clone and the major pathway involved in cytokine signaling, i.e., Janus Kinase (JAK)/Signal transducer and activator of transcription (STAT) [15].